TrialDiabetes care2016

Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial.

Julio Rosenstock et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.